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Abstract
Background: Elevated brain levels of the pleiotropic cytokine interleukin-6, which is mainly secreted from activated
local astrocytes, contribute to pathological events including neuroinflammation and neurodegeneration. Thus,
inhibition of pathological IL-6 expression provides a rationale strategy for targeting the onset or further progression
of neurological disorders including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease and traumatic brain
injury. The purpose of this study was to identify and to characterize new potent inhibitors of astrocytic IL-6
expression for further therapeutic development of novel anti-inflammatory and neuroprotective drugs.
Methods: Oncostatin M (OSM)-treated human glioma U343 cells were used as model for induction of astrocytic IL-
6 expression. This model was characterized by immunoblotting, siRNA technique, ELISA and qRT-PCR and used to
screen low molecular weight compound libraries for IL-6-lowering effects. To validate bioactive compounds
identified from library screens, bacterial lipopolysaccharide was used to induce IL-6 expression in cultivated primary
astrocytes and in mice in vivo. To dissect underlying molecular mechanisms, protein extracts from OSM-treated
U343 cells were analyzed by phospho-specific immunoblotting and immunocytochemistry as well as by co-
immunoprecipitation.
Results: OSM-treatment (100 ng/ml; 24 h) led to 30-fold increase of IL-6 secretion from U343 cells. The temporal
profile of IL-6 mRNA induction displayed a biphasic induction pattern with peak synthesis at 1 h (6.5-fold) and 16 h
(5.5-fold) post stimulation. IL-6 protein release did not show that biphasic pattern and was detected as early as 3 h
post stimulation reaching a maximum at 24 h. The screen of compound libraries identified a set of
heteroarylketones (HAKs) as potent inhibitors of IL-6 secretion. HAK compounds affected the second peak in IL-6
mRNA synthesis, whereas the first peak was insensitive to HAK treatment. HAK compounds also suppressed
lipopolysaccharide-induced IL-6 expression in primary murine astrocytes as well as in brain and plasma samples
from lipopolysaccharide-treated mice. Finally, HAK compounds were demonstrated to specifically suppress the
OSM-induced phosphorylation of STAT3 at serine 727 and the physical interaction of pSTAT3
S727 with p65.
Conclusion: Heteroarylketone compounds are potent inhibitors of IL-6 expression in vitro and in vivo and may
represent a new class of potent anti-inflammatory and neuroprotective drugs.
Keywords: astrocytes, LPS mouse model, IL-6 expression, anti-inflammatory, STAT3 phosphorylation, p65 co-
immunoprecipitation
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Interleukin-6 (IL-6) is a pleiotropic cytokine involved in
several brain diseases as a detrimental factor playing a cau-
sal or exacerbating role in neuroinflammation and neuro-
degeneration [1-7]. Elevated levels of IL-6 are typical for
brains from animal models or humans suffering from
multiple sclerosis, Alzheimer’sd i s e a s e ,P a r k i n s o n ’sd i s e a s e ,
lethal sepsis, meningitis and stroke [8-12]. Additionally,
long-term exposure of neurons or astrocytes to IL-6 as
well as over-activation of IL-6 signaling by IL-6/sIL-6R
fusion protein lead to a robust induction of neuroinflam-
matory response and to neuronal death [6,13-16]. There-
fore, suppression of IL-6 signaling or of IL-6 expression
itself is believed to represent a powerful strategy for the
treatment or prevention of neuroinflammation and subse-
quent neurodegeneration. This is supported by diminished
neuroinflammation induced by spinal cord injury after
infusion of a monoclonal antibody against IL-6 receptor
[17]. Furthermore, the potency of drugs to inhibit IL-6
expression in vitro and in vivo correlates with their anti-
neuroinflammatory and neuroprotective properties
[18-22].
Astrocytes, the main glial cell type of the brain, respond
in general to multiple kinds of acute and chronic brain
insults with a reaction known as astrogliosis [23]. This
reactive astrogliosis involves morphological, structural and
biochemical features including thickened cellular pro-
cesses, increased expression of glial fibrillary protein and
the induction of pro-inflammatory cytokines including
IL-6 [24,25]. Different types of signaling molecules are
able to trigger the astrocytic IL-6 mRNA expression via
distinct intracellular signaling pathways [26]. For example,
lipopolysaccharide (LPS) activates the IL-1 receptor-asso-
ciated kinase (IRAK)-dependent pathway including IB
kinase and nuclear factor B( N F - B) [27]. Another potent
group of IL-6 inducers are cytokines such as tumor necro-
sis factor a, interleukin-1b, oncostatin M (OSM) and leu-
kaemia inhibitory factor (LIF) [28-30]. Interestingly, OSM
and LIF belong together with IL-6 to the same cytokine
family. These IL-6-type cytokines are characterized by
using of glycoprotein gp130 to induce gene expression via
JAK/STAT (Janus kinase/signal transducer and activator
of transcription) and MAPK (mitogen-activated protein
kinase) cascades in a NF-B-dependent manner [31,32].
Thus, blocking of such pathological IL-6-driven gene
expression by low molecular weight inhibitors provides a
possible strategy for targeting the onset or further propa-
gation of astrogliosis and, subsequently, secondary neuro-
nal cell death.
In the present study, the time- and dose-dependent
stimulation of IL-6 expression by OSM was character-
ized in human U343 glioma cells. Subsequently, our
compound libraries were screened for inhibitory effects
on OSM-induced IL-6 expression. We identified bioac-
tive compounds belonging to the chemical class of het-
eroarylketones (HAK). These HAK compounds were
able to suppress the LPS-induced IL-6 expression in
primary mouse and rat astrocytes as well as in an acute
septic shock mouse model in vivo. Finally, the underly-
ing molecular mechanism of HAK compounds interfer-
ing with key signaling molecules of OSM-induced signal
transduction cascade was analyzed. We demonstrate a
selective suppression by HAK compounds of the OSM-
mediated phosphorylation of STAT3 at serine 727,
which affects STAT3 binding to the NF-B subunit p65.
Methods
Primary cultures of murine astrocytes
According to Löffler [33], astrocyte-rich primary cell
cultures were started with brains of newborn mice and
rats and were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) for 33 days at 37°C in a humified
atmosphere with 95% air/5% CO2.
Cell culture
The human glioma cell line U343 [34] was maintained
in DMEM containing 10% fetal bovine serum and
60 μg/ml gentamycin (Invitrogen, Darmstadt, Germany)
at 37°C in a 10% CO2 atmosphere.
Lipopolysaccharide (LPS)-induced acute septic shock
model
A total number of 20 C57/B6 mice at the age of 5 months
with an initial body weight of 22 g to 30 g was analyzed in
this study. Mice were randomly assigned to 2 groups of
control mice (injection of saline or LPS; n = 6 each) and 1
group of LPS-treated mice co-injected with compound
HAK-2 (n = 8). Animals were housed at the Experimental
Animal Core Facility of the University of Leipzig. The
study was approved by the Regierungspräsidium Leipzig,
License # TVV 28/07 on November 14, 2007. To induce
septic shock and acute inflammation, 14 mice were
injected intraperitoneally (i.p.) with 1 mg LPS (Serotyp
055:B5)/kg body weight. Saline injection i.p. was used as
control treatment (n = 6). Compound HAK-2 was co-
injected i.p. to 8 LPS-treated mice at a concentration of 10
mg/kg body weight. Two hours post treatment mice were
sacrificed by CO2 inhalation and tissue samples from hip-
pocampus and cortex as well as plasma were prepared as
described later.
M o u s eb r a i ns a m p l e sf o rq R T - P C Rw e r ep r e p a r e d
f r o m6-8a n i m a l sp e rg r o u p .A f t e rr e m o v a lo ft h e
brain, the tissue samples were flushed shortly with ice
cold saline and placed briefly on filter paper. Cortex and
hippocampus were prepared, weighted and snap frozen
in liquid nitrogen. Samples were stored at -80°C until
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in RNA lysis buffer (Macherey and Nagel, Düren, Ger-
many) using Precellys ceramic beads (diameter of 1.4
mm; Peqlab, Erlangen, Germany).
At the end of the experiment blood samples were col-
lected in ice-cooled tubes and centrifuged within the
next 20 min (10 min, 1500 × g, 4°C). Plasma samples
were aliquoted into fractions of 50 μl, shock frozen and
stored at -80°C until analysis.
Quantitative real-time PCR
Total RNA of cultured cells and homogenized mouse
brain tissue samples was isolated using RNA isolation kit
“NucleoSpin RNA II” from Macherey and Nagel. RNA
quantity was measured by spectrophotometrical quantifi-
cation (NanoDrop 2000, Peqlab, Erlangen, Germany).
Total RNA (0.5 μg) was transcribed to cDNA using Super-
script III and oligo-dT primer (Invitrogen, Darmstadt,
Germany). Quantitative real-time PCR was performed
with QuantiFast SYBR Green PCR Master mix (Qiagen,
Hilden, Germany) using Rotorgene 3000 system (Corbett,
Sydney, Australia). Gene expression was normalized to the
expression of three reference genes glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), glucose-6-phosphate
dehydrogenase (G6PDH) and hypoxanthine-guanine phos-
phoribosyltransferase (HPRT). Primers for PREP (5’-
TGAGCAGTGTCCCATCAGAG-3’;5 ’- CATCTTCGCT-
GAACGCATAA-3’)a n dI L - 6( 5 ’-AAAGGACGTCAC
ATTGCA-3’;5 ’-GCCTCAGACATCTCCAGTCC-3’)w e r e
designed using the Primer3 Software (http://frodo.wi.mit.
edu/). Data were analyzed by Rotorgene 3000 Software
version 6.0 by comparative quantitation. The appropriate
size of PCR products was confirmed by gel-electrophoresis
stained with ethidium bromide.
ELISA
Measurements of IL-6 in conditioned medium and mur-
ine plasma samples were done by means of human- or
murine-specific IL-6 Cytoset kits (Invitrogen, Darmstadt,
Germany) according to manufacturer’s protocols.
Preparation of whole-cell extracts for western blotting
and immunoprecipitation
Human U343 cells were lysed with cell lysis buffer (Invitro-
gen, Darmstadt, Germany) supplemented with 0.2 mg/ml
sodium orthovanadate (Sigma, Taufkirchen, Germany),
protease inhibitor mix complete mini (Roche, Mannheim,
Germany) and 1 mM AEBSF (Sigma, Taufkirchen, Ger-
many) for 30 min on ice. Lysates were centrifuged for 15
min at 15,000 × g and 4°C. Protein content in supernatants
was quantified by Bradford assay (Sigma, Taufkirchen, Ger-
many) according to the manufacturer’s protocol and stored
at -20°C.
Western blotting
Western blotting was performed with 30 μgp r o t e i no f
whole-cell extracts, mixed with 4 x SDS sample loading
buffer (Invitrogen, Darmstadt, Germany) and denatured
for 10 min at 85°C. Cell extracts separated by 4 - 12%
Novex Bis-Tris Mini Gel system (Invitrogen, Darmstadt,
Germany) were transferred to Roti-NC nitrocellulose
membranes (Roth, Karlsruhe, Germany). Membranes were
probed with primary antibodies against STAT3 (#9132)
and P-STAT3
S727 (#9134) from Cell Signaling (Frankfurt/
M., Germany) as well as with anti-atubulin (Sigma, Tauf-
kirchen, Germany) to confirm equal loading and blotting
of protein samples. Proteins were visualized using HRP-
conjugated secondary antibodies (1:4000, cell signaling,
Frankfurt/M., Germany) and the SuperSignal West Pico
system (Thermo Fisher Scientific, Karlsruhe, Germany).
Small interfering RNA (siRNA)
Human U343 cells (0.25 × 10
6) were seeded in 24-well
plates (Greiner, Frickenhausen, Germany) and trans-
fected immediately with 2.5 μl A. dest. (mock), 100 μM
non-target control (NTC) or PREP-specific siRNA ON-
TARGETplus SMARTpool (#L-006006-00, Dharmacon,
Schwerte, Germany) using DharmaFECT 1 siRNA trans-
fection reagent (Dharmacon, Schwerte, Germany)
according to the manufacturer’sp r o t o c o l .A f t e r4 8h
adherent cells were transfected a second time under
identical conditions for further 24 h and subsequently
stimulated with OSM (100 ng/ml) for additional 6 h.
For IL-6 specific ELISA 5 - 40 μl of conditioned media
w e r eu t i l i z e d .T oa n a l y z eI L - 6m R N Ae x p r e s s i o nb y
qRT-PCR, total RNA was isolated and reversely tran-
scribed as described above.
Immunocytochemistry
Human U343 cells (1 × 10
5 cells/well) were grown on
cover slips in 24-well plates (Greiner, Frickenhausen,
Germany) for 24 h. After the time of treatment indicated
cells were fixed in ice-cold methanol for 10 min on ice,
and then incubated with rabbit anti-phospho-STAT3
antibody (#9134, Cell Signaling, Frankfurt/M., Germany)
overnight at 8°C. Subsequently, cells were incubated with
goat anti-rabbit IgG Cy2-conjugated secondary antibody
(Dianova, Hamburg, Germany) at room temperature for
45 min. Finally, cover slips were mounted on microscope
slides and approximately 250 cells/sample were evaluated
densitometrically by fluorescence microscopy (Zeiss,
Jena, Germany) and MetaMorph Image Analysis Software
(Universal Imaging Corporation, USA).
Immunoprecipitation
Cell lysates from 4 × 10
6 U343 cells/sample were
obtained as described above. From each sample 200 μg
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bit anti-p65 antibody (Santa Cruz Biotechnology; Hei-
delberg, Germany) or A. dest. (control) overnight at 4°C.
Immunoprecipitated samples were incubated with 20 μl
Dynabeads Protein G (Thermo Fisher Scientific, Karls-
ruhe, Germany) for 1 h at 4°C. Beads were washed 3
times with 1 ml PBS. Preparation of samples for SDS-
PAGE analysis was done by means of dilution with
SDS-PAGE sample buffer (Invitrogen, Darmstadt, Ger-
many), followed by denaturation at 90°C for 10 min.
SDS-PAGE analysis were performed as described before.
PREP enzymatic activity assay
The activity of human recombinant prolyl endopeptidase
(PREP) was determined photometrically using the
substrate Z-Gly-Pro-pNA (Bachem, Weil am Rhein,
Germany) usually at a concentration of 150 μM. As assay
buffer 50 mM HEPES buffer pH 7.6, containing 200 mM
NaCl, 1 mM EDTA, and 1 mM dithiothreitol was used.
Release of pNA was monitored continuously at 405 nm
for 15 min at 30°C in a 96-well plate reader (Spectrafluor,
Tecan, Crailsheim, Germany). PREP activity was calculated
from the slope of the time product curve with the help of
a pNA standard [35]. For determination of Ki values three
different substrate concentrations (62.5 μM; 125 μM and
250 μM) and seven different inhibitor concentrations were
analyzed. Substrate concentrations were selected to be at
the Km value of Z-Gly-Pro-pNA (125 μM) as well as half
and twice the Km. Data were fitted by non-linear regres-
sion to the competitive inhibitor equation (Graphit 5.0,
Erithacus software).
Statistical analyses
Values are expressed as mean ± SD. Standard unpaired t
test was used for analyses of statistically significance.
Differences between treatments were considered signifi-
cant when p < 0.05.
Results
Oncostatin M-mediated release of IL-6 in human U343
glioma cells
Beside myocytes and adipocytes, glial cells are represent-
ing the most prominent source of the cytokine IL-6 in
mammals and play an important role in neuroinflamma-
tory processes [23,36]. Therefore, the human glioma cell
line U343 was selected for screening of IL-6-lowering
effects of our in-house compound libraries. Preceding
experiments with a set of stimuli known from literature
to induce IL-6 expression in astroytes [30,37], identified
Oncostatin M (OSM) as a robust inductor of IL-6 protein
release in our experimental setup (data not shown).
The dose- and time-dependent stimulation of IL-6
expression by OSM in U343 cells is characterized in
figure 1. To analyze dose dependence of IL-6 release,
U343 cells were treated for 24 hours with various con-
centrations of OSM followed by measurement of IL-6
protein concentrations in the conditioned medium by
a specific ELISA. OSM induced the release of IL-6 in a
dose-dependent manner with an EC50 of 70.5 ± 22.68
ng/ml (Figure 1A). Therefore, all further investigations
were performed with 100 ng/ml OSM. The highest
dose of 200 ng/ml OSM led to 30-fold increase of IL-6
accumulation in the conditioned media in comparison
to vehicle-treated cells.
To analyze the time-course of OSM-induced IL-6
expression, U343 cells were incubated with OSM for dif-
ferent periods of time as indicated in figure 1B. Amounts
of IL-6 mRNA and protein were subsequently quantified
by qRT-PCR and by ELISA, respectively. Time course
studies revealed that IL-6 mRNA displays a biphasic
induction pattern with peak synthesis at 1 h (6.5-fold)
and 16 h (5.5-fold) post stimulation. Significant induction
Figure 1 OSM induces dose- and time-dependent IL-6
expression in human U343 glioma cells. OSM treatment leads to
dose-dependent IL-6 release (A). U343 cells were stimulated with
different concentrations of OSM as indicated. After 24 hours the
conditioned medium was analyzed by IL-6-specific ELISA. The time-
dependent profile of OSM treatment shows a significant increase in
IL-6 mRNA expression and protein secretion (B). U343 cells were
stimulated with 100 ng/ml OSM and harvested at time points
indicated to extract total RNA or whole cell lysate. IL-6 mRNA
expression was analyzed by qRT-PCR (dotted line, black triangles)
and IL-6 protein release by ELISA (solid line, black squares). All data
points, presented as mean ± SD, are from experiments carried out
in quadruplicate. ns, not significant; *p < 0.05; ***p < 0.001.
Schulz et al. Journal of Neuroinflammation 2011, 8:86
http://www.jneuroinflammation.com/content/8/1/86
Page 4 of 13of IL-6 protein was detected in the conditioned medium
as early as 3 h post stimulation and reaching a maximum
at 24 h. In contrast to the mRNA expression profile, IL-6
protein release did not show a biphasic pattern.
Identification of compounds reducing OSM-induced IL-6
release in human U343 glioma cells
Using the characterized cell culture model of OSM-
induced IL-6 expression, our in-house compound libraries
were screened for potent IL-6 expression inhibitors.
Human U343 glioma cells were treated with 100 ng/ml
OSM for 24 h. The analysis by IL-6 ELISA identified a set
of structurally related compounds as potent inhibitors of
IL-6 secretion (Table 1). Interestingly, all bioactive com-
pounds identified belong to the class of heteroarylketones
(HAK) and differ from each other at residues R to R’’ and
P1,P 1’ and P2, respectively (Figure 2). HAKs with proline
in position P1 are known from the literature as inhibitors
of prolyl endopeptidase (PREP), a proline-specific serine
protease [38]. Determination of the Ki values proved that
compounds with proline in position P1 are highly potent
inhibitors of PREP. The remaining compounds with a sub-
stituted moiety in that region showed very poor PREP
inhibition (Table 1).
While PREP inhibitor compounds HAK-1, HAK-2,
HAK-5, HAK-6 and HAK-7 significantly reduced OSM-
induced IL-6 secretion, there was no intimate correla-
tion between the extent of PREP inhibition and the
potency to suppress the IL-6 expression for different
HAK compounds (Table 1). For example, compound
HAK-8 is a potent PREP inhibitor but does not reduce
OSM-stimulated IL-6 secretion (Table 1). On the other
hand, compounds HAK-3 and HAK-4 are poor PREP
inhibitors but significantly reduced OSM-stimulated IL-
6 secretion (Table 1). This indicates that HAKs reduce
IL-6 secretion independent from their PREP-inhibiting
activity. In contrast to PREP inhibition, the proline
residue at position P1 can be replaced by other amino
acid residues like alanine or leucine without loss the
bioactivity to reduce IL-6 expression. To clarify the role
of PREP in the regulation of IL-6 expression, PREP was
knocked down by siRNA technique in U343 cells. The
remaining mRNA expression level of PREP was lower
than 15% in comparison to mock and to non-target con-
trol (NTC) siRNA sample (Figure 3A). Interestingly, 6 h
after onset of OSM stimulation, a 2-fold higher PREP
mRNA level was obtained in non OSM-treated cells
compared to OSM-stimulated NTC and mock samples.
Table 1 Effects of HAK compounds on PREP inhibition and on OSM-stimulated IL-6 secretion from U343 cells
Compound Z-P2-P1-P1’ Remaining IL-6 expression [% of control] PREP assay (Ki [M]
HAK-1 Z-Phe-Pro-BTh 15.9 ± 1.87 4.6 × 10
-9
HAK-2 Z-Ala-Pro-BTh 18.7 ± 3.87 3.8 × 10
-11
HAK-3 Z-Phe-Leu-BTh 22.1 ±5.91 > 1.0 × 10
-6
HAK-4 Z-Phe-Ala-BTh 35.1 ± 6.75 > 1.0 × 10
-5
HAK-5 Z-Phe-Pro-Th 35.2 ± 12.92 1.1 × 10
-10
HAK-6 Z-Lys-Pro-BTh 38.8 ± 5.26 4.1 × 10
-9
HAK-7 Z-Asp-Pro-BTh 52.8 ± 3.91 1.2 × 10
-8
HAK-8 Z-Arg-Pro-BTh 96.8 ± 10.69 3.2 × 10
-9
HAK-9 Z-Phe-Phe-BTh 182.8 ± 25.41 > 1.0 × 10
-5
IL-6 values are expressed as mean ± SD. IL-6 release of vehicle-treated cells was set to 100% (n = 2). Seven out of 9 HAK compounds suppressed significantly the
OSM-induced IL-6 release. There was no intimate correlation between significant IL-6 reduction (bold) and the potency of HAK compounds to inhibit activity of
recombinant prolyl endopeptidase (bold), presented as Ki values. All amino acids were used in L-configuration. Z, benzyloxycarbonyl, BTh, benzothiazole, Th,
thiazole.
Figure 2 General structures of IL-6 lowering HAK compounds.
All bioactive compounds are structurally related and belong to the
class of HAKs containing either thiazole (A; -Th) or benzothiazole (B;
-BTh) as reactive moiety at P1’.
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experimental conditions is not known, but could involve
similar mechanisms contributing to induction of PREP
in glial cells in experimental animals [39]. Compound
HAK-2 did not have an effect on this phenomenon,
allowing to investigate the effect of siRNA-mediated
PREP knock down on OSM-stimulated IL-6 expression.
Contrary to compound HAK-2, neither IL-6 mRNA
level nor IL-6 protein level in the conditioned medium
was significantly reduced after specific knock down of
PREP (Figures 3B and 3C). This result strongly indicates
that PREP is not involved in regulation of IL-6 expres-
sion by HAKs. Therefore, we conclude that HAKs exert
their effects on IL-6 expression independent from PREP
inhibition by modulating at least a second molecular
target.
Effect of HAK compounds on OSM-induced IL-6 mRNA
expression
To reveal whether bioactivity of HAK compounds is
based on suppression of IL-6 protein biosynthesis or on
interference with IL-6 mRNA expression OSM-treated
U343 cells were incubated with 20 μMo fc o m p o u n d
HAK-2 for different periods of time. Time course ana-
lyses revealed a strong inhibition of the OSM-induced
IL-6 mRNA expression by compound HAK-2 (Figure 4).
Notably, only the second peak in IL-6 mRNA synthesis
at 6 h post stimulation was affected, whereas the first
peak 1 h post stimulation was insensitive to HAK-2
treatment. Additional experiments demonstrated sup-
pression of OSM-induced IL-6 expression in U343 cells
by HAK compounds even after delayed onset of treat-
ment 6 h after OSM stimulation (data not shown).
Therefore, it is very likely that the relevant molecular
target of HAK compounds is involved in the OSM-
induced signal transduction process not earlier than 6 h
after onset of the stimulation.
Figure 3 Effect of PREP knock down on OSM-induced IL-6 expression in U343 cells. PREP knock down does not suppress OSM-induced IL-
6 expression in U343 cells, whereas the compound HAK-2 reduces IL-6 levels under identical test conditions. U343 cells were transfected with
PREP-specific siRNA and non-target control siRNA (NTC) or vehicle (control). After 48 h cells were transfected again for further 24 h followed by
OSM-stimulation for 6 h. As positive control, only vehicle transfected cells were treated with compound HAK-2 (20 μM). Expression levels of PREP
(A) and IL-6 mRNA (B) were measured by qRT-PCR, while conditioned media were used for quantification of IL-6 release by ELISA (C). ns, not
significant; **p < 0.01; ***p < 0.001.
Figure 4 Time course of OSM-induced IL-6 mRNA expression in
U343 cells treated with compound HAK-2. Compound HAK-2
completely suppresses exclusively the second IL-6 mRNA expression
peak. U343 cells were stimulated with 100 ng/ml OSM and treated
with 0.1% DMSO as solvent control (solid line, black triangle) or 20
μM HAK-2 (dashed line, white triangle). Samples were harvested at
time points indicated to extract total RNA. IL-6 mRNA expression
was analyzed by qRT-PCR. All data points are presented as mean ±
SD, and were obtained from experiments carried out in
quadruplicate. Statistical analysis were performed between control
and HAK-2 samples from same time point. ns, not significant;
***p < 0.001.
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performed with actinomycin D, a transcription arresting
agent, to study whether the strong inhibition of IL-6
mRNA expression by HAK compounds was based on
modified mRNA stability. No difference in mRNA stabi-
lity was observed between treated and non-treated cells
(data not shown), demonstrating that the HAK com-
pound-mediated suppression of IL-6 mRNA is most
likely due to inhibition of transcription rather than
modified mRNA stability.
Suppression of LPS-induced IL-6 release by HAK
compounds in primary murine astrocytes
To analyze whether inhibition of OSM-induced IL-6
expression is a cell line-specific effect or a common fea-
ture of HAK compounds and valid in general, primary
murine astrocytes were treated with HAK compounds.
In contrast to human U343 glioma cells, OSM treatment
did not lead to an increased IL-6 expression in mouse
and rat primary astrocytes (data not shown). However,
LPS significantly induced IL-6 release into the condi-
tioned medium of mouse and rat astrocyte cultures
(Figure 5).
Primary murine astrocytes stimulated with 1 μg/ml
LPS were co-treated with compounds HAK-2 and HAK-
5 at a concentration of 20 μMe a c hf o r2 4h .T h e
observed effect of compounds HAK-2 and HAK-5 on
LPS stimulation was similar to that of OSM-induced IL-
6 expression in human U343 glioma cells (Figures 5A
and 5B). In comparison to untreated samples LPS-
induced IL-6 expression was reduced by 60% in mouse
and 50% in rat astrocytes by both HAK compounds.
Thus, suppression of both, LPS- and OSM-induced IL-6
expression in different cell types by structurally related
compounds is another indication for strong potency
of HAK compounds to target neuroinflammatory
processes.
Potent inhibition of IL-6 upregulation by compound
HAK-2 in vivo
B a s e do nt h er e s u l t so b t a i n e df r o mp r i m a r ym u r i n e
astrocytes, we reasoned that HAK compounds might
also suppress elevated IL-6 expression in vivo.T h e r e -
fore, bioactivity of the compound HAK-2 was analyzed
in the LPS-induced mouse septic shock model. In pre-
paration of this in vivo study, selected HAK compounds
were characterized in detail concerning brain bioavail-
ability. It was demonstrated by quantitative analysis of
mouse plasma and brain samples using LC-MS/MS that
the compounds are bioavailable and able to pass the
blood brain barrier (data not shown). For further in vivo
investigations compound HAK-2 with a logBB of -0.22
was selected.
Intraperitoneal injection of 1 mg/kg LPS into C57/B6
mice resulted in an acute elevation of IL-6 concentra-
tion in plasma, hippocampus and cortex 2 h post
administration (Figures 6A-C). The plasma level of IL-6
protein was significantly reduced by 55% in mice treated
with 5 mg/kg HAK-2 in parallel as compared to LPS
alone (Figure 6C). Similar effects of HAK-2 treatment
were observed for induced IL-6 mRNA in hippocampus
(60%) and cortex (53%) (Figures 6A and 6B). These data
clearly show the strong potency of HAK compounds to
modify IL-6 expression in vivo.
Effect of HAK compounds on OSM-mediated
phosphorylation of signal transducer and activator of
transcription 3 (STAT3) and extracellular signal-regulated
kinase 1 (Erk1)
The activation of the OSM signaling cascade resulting in
the stimulation of IL-6 expression is known to involve
intracellular phosphorylation events [31,40,41]. Therefore,
effects of HAK compounds on the OSM-induced phos-
phorylation of signal transducer and activator of transcrip-
tion 3 (STAT3) and extracellular signal-regulated kinase 1
(Erk1) were investigated. Since HAK compounds were
shown to be bioactive 3 to 6 h post stimulation, U343 cells
were incubated with OSM for 6 h. In contrast to non-sti-
mulated control, OSM induced phosphorylation of Erk1
as well as STAT3 6 h post stimulation. Interestingly, HAK
compounds suppressed STAT3 phosphorylation at serine
727 (pSTAT3
S727) (Figure 7), but neither phosphorylation
of pSTAT3
Y705 nor pErk1/2
T202/Y204 (data not shown).
Compound HAK-8 showed a significantly lower effect on
pSTAT3
S727 phosphorylation. This observation correlates
well with the missing effect of compound HAK-8 on IL-6
expression as shown in Table 1. HAK compound-specific
suppression of OSM-induced pSTAT3
S727 was confirmed
Figure 5 Suppression of LPS-induced IL-6 release in primary
murine astrocytes by selected HAK compounds. Compounds
HAK-2 and HAK-5 significantly reduce LPS-induced IL-6 release in
primary mouse (A) and rat astrocytes (B). Astrocytes derived from
newborn mice and rats were cultivated for 33 days followed by
stimulation with 1 μg/ml LPS and treatment with compounds HAK-
2 and HAK-5 (20 μM). After 24 hours conditioned media were
analyzed with IL-6 specific ELISA. Data (mean ± SD) were obtained
from experiments carried out in quadruplicate and statistical analysis
was performed using the paired t test. Amount of IL-6 in LPS-
treated control sample was set to 100%. ns, not significant; **p <
0.01; ***p < 0.001.
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Page 7 of 13by immunocytochemistry (Figures 7B-C). U343 cells culti-
vated on cover slips were treated identically as described
before. In figure 7A an example of HAK compound effi-
ciency to suppress nuclear pSTAT3
S727 phosphorylation 6
h post OSM stimulation is shown. Nuclear localization
was confirmed by DAPI staining (data not shown). In fig-
ure 7C densitometric results of at least 3 independent
experiments are summarized. While compounds HAK1-7
significantly suppressed the OSM-mediated phosphoryla-
tion of pSTAT3
S727, compound HAK-8 did not. Results
from western blot analyses and immunocytochemistry are
strongly correlating with each other. Thus, it appears that
the IL-6 reducing bioactivity of HAK compounds is most
likely based on suppression of STAT3 phosphorylation at
serine 727.
STAT3 and NF-B subunit p65 are forming a OSM-
dependent complex which is sensitive to HAK
compounds
Normally, STAT3 is activated by phosphorylation at tyro-
sine 705, which induces dimerization, nuclear transloca-
tion and DNA binding. In contrast to other transcription
factors like NF-B, Creb and c/EBPb, STAT3 can not
bind directly to the IL-6 promoter, because there are no
STAT3 binding elements present. It is known from lit-
erature that several forms of interactions and cross talks
between NF-B and STAT3 exist. For instance, recent
studies have shown a physical interaction between
STAT3 and NF-B [42,43]. The importance of
pSTAT3
S727 for protein interactions are under discussion
[42,44]. However, there is no information so far on the
role of pSTAT3
S727 for the interaction with NF-B. To
characterize a possible OSM-induced and p
S727-depen-
dent complex formation between STAT3 and NF-B, we
performed co-immunoprecipitation of p65 followed by
western blotting for STAT3. In this experiment, U343
glioma cells were stimulated with OSM for 6 h in the
absence or presence of compound HAK-2. The immuno-
precipitation analysis showed that STAT3 and p65 were
co-immunoprecipitated in a OSM-dependent manner
(Figure 8). Furthermore, treatment of human U343
glioma cells with compound HAK-2 led to a clear reduc-
tion of p65-mediated STAT3 co-immunoprecipitation.
Moreover, these data confirm OSM- and phosphoryla-
tion-dependent complex formation between STAT3 and
p65, which is sensitive to HAK compounds.
Discussion
Neuropathological situations with extended astroglial
activation are associated with increased levels of pro-
inflammatory mediators including IL-6. In vitro and in
vivo studies have demonstrated that IL-6 plays a pivotal
role in the initiation of neuroinflammatory cascades and
in secondary neuronal cell death [6,45]. Thus, preven-
tion of the neuroinflammatory response to primary
lesions has a neuroprotective potential.
T h ep r e s e n ts t u d yw a sp e r f o r m e dt oi d e n t i f yn e w
small molecular weight inhibitors acting on the pathway
that results in IL-6 expression. For screening of our in-
house compound libraries the human glioblastoma cell
Figure 6 Suppression of LPS-induced IL-6 expression in vivo by compound HAK-2.C 5 7 / B 6m i c e( 5m o n t h so l d )w e r ei n j e c t e d
intraperitoneally (i.p.) with saline (control group, n = 6) or with 1 mg LPS/kg body weight (LPS group, n = 6). Compound HAK-2 (10 mg/kg
body weight) was co-injected i.p. with LPS (LPS + HAK-2 group, n = 8). After 2 hours treatment, samples from hippocampus (A), cortex (B) and
plasma (C) were prepared and analyzed by qRT-PCR and ELISA, respectively. Data obtained were normalized by means of mRNA level of 3
reference genes (glyceraldehyde 3-phosphate dehydrogenase, glucose-6-phosphate dehydrogenase and hypoxanthine-guanine
phosphoribosyltransferase). Results are shown as induction factors compared to those of saline-treated mice (given as factor 1). Statistically
significant differences between LPS group and LPS + HAK-2 group were calculated using the unpaired t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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Page 8 of 13line U343 was used, because glioblastoma cell lines were
shown to respond with increased IL-6 expression to dif-
ferent neuroinflammatory stimuli like LPS [27], Sub-
stance P [46], tumor necrosis factor a, interleukin-1b,
leukemia-inhibitory factor and OSM [30]. Analysis of
conditioned media revealed, that in our experimental
setup only OSM treatment significantly induced the
expression of IL-6 in human U343 glioma cells. This
result is consistent with published data, showing that
U343 cells express the OSM-receptor components LIFR
and OSMRb as well as the common signal transducer
gp130 [47]. Furthermore, the OSM-mediated activation
of signal components of the Jak/STAT- and MAPK-
pathways was described for U343 and U373 glioma
cells, respectively [32]. We observed a biphasic
Figure 7 Effect of selected HAK compounds on OSM-induced STAT3 phosphorylation at serine 727 in U343 cells. Treatment of U343
cells with HAK compounds led to a significant reduction of OSM-induced pSTAT3
S727, while STAT3 expression was not affected. For western blot
analysis (A) 0.25 × 10
6 cells co-treated for 6 h with OSM (100 ng/ml) and selected HAK compounds (20 μM) were extracted and analyzed as
described in experimental procedures. Blots (30 μg protein/lane) were probed with STAT3 and pSTAT3
S727-specific antibodies (1:500, overnight).
For immunocytochemistry (B) 0.1 × 10
6 cells were grown on cover slips and treated identically as described above. Post treatment, cells were
fixed in methanol and labeled with a pSTAT3
S727-specific antibody (1:200, overnight). From each sample 15 images were taken by means of
fluorescence microscope and app. 250 cells/sample were densitometrically analyzed by MetaMorph imaging software (C). Mean signal intensity
of OSM-treated control cells was set to 100%. All data are presented as mean ± SD from experiments carried out in triplicate. ns, non significant;
***p < 0.001.
Figure 8 Effect of compound HAK-2 on OSM-induced STAT3/
p65 complex formation in U343 cells. OSM treatment led to
increased STAT3/p65 complexation, which is suppressed by
compound HAK-2. U343 cells were stimulated with 100 ng/ml OSM
and co-treated with compound HAK-2 (20 μM) for 6 h. After
treatment, cells were lysed and whole-cell extracts were
immunoprecipitated with a polyclonal antibody against the NF-B
subunit p65 or vehicle (control). Immunoblots were prepared and
probed with polyclonal antibody against STAT3. Data from a
representative experiment (n = 2) are shown.
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Page 9 of 13induction pattern of OSM-induced IL-6 mRNA expres-
sion, which was described earlier also for human U373
astroglioma cells [32]. The time-course is characterized
by a first strong, rapid and transient IL-6 mRNA expres-
sion peak at 1 h followed by a second one at 6 h with a
less strong, but prolonged induction. The same type of
expression pattern was observed for tissue factor mRNA
in OSM-treated smooth muscle cells [48]. Thus, bipha-
sic induction seems to be an OSM-specific feature with
general relevance for OSM action.
All potent inhibitors of IL-6 secretion identified in the
compound library screen (see Table 1) belong to the che-
mical class of HAK and are structurally related to inhibi-
tors of PREP [38]. This observation is in line with the
hypothesis, that PREP is involved in regulation of intra-
cellular protein transport and secretion [49]. However,
there was no correlation between PREP siRNA- (knock-
down) and pharmacological inhibition of PREP on one
hand and the potency of these compounds to suppress
the OSM-induced IL-6 expression on the other. Further-
more, our data on the temporal profile of IL-6 suppres-
sion suggest that the bioactivity of HAK compounds is
most likely based on interference with IL-6 mRNA synth-
esis but not on disturbed intracellular transport and
secretion mechanisms. Therefore, PREP can be excluded
as the IL-6 relevant molecular target of HAKs and HAK
compounds appear to interact with at least one further
molecular target. Interestingly, only the second IL-6
mRNA peak was affected by HAKs indicating that the
molecular target of HAK compounds is involved 3 to 6 h
post OSM stimulation at earliest. Theoretically, the biolo-
gical target of HAKs can pre-exist in untreated cells or be
induced by OSM treatment and subsequently incorpo-
rated in signaling pathways. Notably, in an experiment
analyzing the puromycin sensitivity of OSM-induced IL-
6 mRNA expression, it was demonstrated that OSM
induces the protein synthesis of signaling molecules
essential for the second IL-6 mRNA expression peak
[32]. Whereas puromycin completely abrogated the sec-
ond IL-6 expression peak it showed no effect on the first
OSM-induced IL-6 mRNA peak. This demonstrates a
requirement for de novo protein synthesis exclusively for
the second IL-6 expression peak of this biphasic response
signaling. The relationship between HAK-mediated sup-
pression of OSM-induced IL-6 release and the effect of
HAK compounds exclusively on the second mRNA peak
suggests that more than 75% of secreted IL-6 is based on
the second phase of OSM-induced IL-6 mRNA expres-
sion. Thus, the mRNA induced in the first phase appears
to have regulatory functions rather than acting as a tem-
plate in protein synthesis. S u c har e g u l a t o r yr o l eo f
mRNA molecules was recently described by Poliseno et.
al. [50] showing that mRNA molecules from pseudogenes
or long non-coding RNAs can act as competitive endo-
genous RNAs sequestering microRNA molecules.
To elucidate whether the HAK-mediated suppression
of OSM-induced IL-6 expression is cell line-specific or
valid in general, experiments with primary murine astro-
cytes were performed. In contrast to human U343 glio-
blastoma OSM did not induce IL-6 expression in mouse
and rat primary astrocytes. However, LPS, known to act
as a powerful stimuli of cytokines [51], significantly
increased IL-6 expression in primary murine astrocytes.
Co-treatment with HAK compounds markedly sup-
pressed levels of OSM-stimulated IL-6 expression in both
rat and mouse astrocytes. These data demonstrate that
the anti-inflammatory bioactivity of HAKs is not limited
to a single OSM-based cell culture model but also valid
for a series of pathophysiological conditions contributing
to neuroinflammation and neurodegeneration.
We were also interested to reveal whether HAK com-
pounds are bioactive under inflammatory conditions in
vivo. For this study, compound HAK-2 was selected
based on its beneficial features concerning toxicity, bioa-
vailability and blood brain barrier passage. In accordance
with the data obtained from primary murine astrocytes,
compound HAK-2 significantly suppressed LPS-induced
IL-6 levels in brain- and plasma-derived samples from
septic mice. This result strongly indicates the anti-
inflammatory potency of HAK compounds in vivo for
possible treatment of central nervous system diseases.
To get more information about the underlying molecu-
lar mechanism of HAK bioactivity, the signal-transduc-
tion pathways involved in OSM-mediated IL-6
expression were dissected in more detail. Interestingly,
LPS- and OSM-induced signal pathways are based on the
same molecular mechanism such as STAT3 or NF-B
activation [31,52], indicating that HAK compounds may
target a common cellular event. Two major signaling cas-
cades the JAK/STAT as well as the MAPK pathways are
switched on by binding of OSM to the receptor heterodi-
mers OSMR/gp130 or LIFR/gp130 [53]. Subsequent acti-
vation of signal tyrosine kinases of the JAK family leads
to phosphorylation of pivotal signal molecules such as
STAT3 and Erk1 and 2 respectively [31,32]. The essential
role of receptor subunits as well as of downstream signal-
ing molecules as STAT3, Erk1 and p65 for OSM-trig-
gered IL-6 expression in U343 cells was confirmed by
siRNA-based knock-down experiments (data not shown).
Furthermore, Erk1/2 and STAT3 were phosphorylated 6
h post OSM treatment, which was identified as the criti-
cal time point for the HAK bioactivity. Immunoblotting
and immunofluorescence experiments revealed that
neither OSM-induced pErk1/2
T202/Y204 phosphorylation
nor pSTAT3
Y705 phosphorylation were modified by HAK
compounds. However, HAK treatment led to a significant
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Page 10 of 13reduction of OSM-stimulated pSTAT3
S727 phosphoryla-
tion. Importantly, the HAK-based inhibition profiles for
IL-6 expression and pSTAT3
S727 phosphorylation are
strongly correlating with each other. Thus, suppression
of OSM-induced phosphorylation of pSTAT3
S727 is most
likely the relevant molecular mechanism of the HAK
compound bioactivity to suppress IL-6 expression. In
contrast to pSTAT3
Y705, which is essential for dimeriza-
tion, nuclear translocation and DNA binding [54,55], the
physiological role of pSTAT3
S727 is discussed controver-
sially [56-59]. Depending on the specific promoter and/
or the cellular context pSTAT3
S727 can influence tran-
scriptional activity of target genes [60,61].
However, in the case of the IL-6 promoter, where acti-
vated NF-B binds directly to DNA, no cis-regulatory
elements for STAT3 binding were identified so far
[62-64]. Based on these observations, we hypothesize
that pSTAT3
S727 may regulate IL-6 gene expression by
an alternative pathway. It is known that STAT3 is com-
plexed with transcription factors such as c-Jun, c-Fos,
forkhead and endothelial cell-derived zinc finger protein,
respectively [65-68]. Furthermore, it was shown that
physical interaction of the STAT3 DNA-binding domain
with the NF-B subunit p65 led to a reduced promoter
activity of inducible nitric oxide synthase gene [69].
Together, these findings strongly suggest that physical
interaction between STAT3 and p65 may result in a
functional coupling important for the STAT3-dependent
regulation of p65 responsive genes. Indeed, we here
demonstrated by co-immunoprecipitation that p65 and
STAT3 interact with each other in an OSM-dependent
manner. Noteworthy, the OSM-stimulated STAT3 and
p65 complex formation is quite sensitive against treat-
ment with HAK compounds. This supports our hypoth-
esis and indicates for the first time a regulatory function
for pSTAT3
S727 in OSM-triggered STAT3/NF-B
interaction.
In summary, HAK compounds selectively target the
expression of genes with promoters co-regulated by
pSTAT3
S727-dependent signaling. Based on this mechan-
ism, kinases phosphorylating STAT3 at serine 727 such as
MAPKs, mTOR, NLK and PKCδ may represent direct
molecular targets of HAK compounds. Thus, further stu-
dies are required to identify the precise molecular
mechanisms and the neuroinflammatory-related genes
sensitive to HAK-treatment. This will enable the therapeu-
tic development of HAK compounds for treatment of neu-
rological diseases including Alzheimer’s disease, multiple
sclerosis, Parkinson’s disease and traumatic brain injury.
Conclusions
In the present study, we identified and characterized for
the first time HAK compounds as potent inhibitors of
OSM- and LPS-induced IL-6 expression in vitro and in
vivo. The molecular trigger of HAK bioactivity is most-
likely a selective suppression of STAT3 phosphorylation
at serine 727. Pathological upregulation of astrocytic
IL-6 expression is known to play a pivotal role in onset
and progression of neurological diseases including Alz-
heimer’s disease, multiple sclerosis, Parkinson’s disease
and traumatic brain injury. In conclusion, we propose
that HAK compounds represent a new potent class of
drugs for treatment or prevention of neuroinflammation
and subsequent neurodegeneration.
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